KNOWLEDGE, ATTITUDE AND COVERAGE OF DIFFERENT COVID-19 VACCINES AMONG GENERAL POPULATION OF DISTRICT MUZAFFARABAD, AJ&K, PAKISTAN

Main Article Content

Abdul Rauf
Areeba Hafeez
Syed Ayaz Kazmi
Muhammad Zahid Latif
Beenish Shahid
Tasleem Akhtar
Sundus Khawaja
Nuzhat Shafi
Zeeshan Anjum
Mohsin Nazeer Awan
Salma Farooq
Muqaddas Tahir
Raja Awais Mumtaz
Faisal Farooq

Keywords

Coverage of Covid-19 vaccines, Knowledge and Attitudes towards Covid-19 vaccines, Covid-19, Covid-19 in Azad Kashmir, Vaccine coverage of Covid-19 in AJ&K, Vaccination of Covid-19 in Muzaffarabad

Abstract

Background: The highly contagious respiratory disease, COVID-19, originating from the SARS-CoV-2 virus, has rapidly spread globally, causing significant human suffering and economic losses. This study in district Muzaffarabad, AJ&K, Pakistan, focuses on assessing knowledge, attitude, and coverage of diverse COVID-19 vaccines among the general population.


Methods: Executing a cross-sectional survey, data from every union council in district Muzaffarabad was collected, incorporating both primary and secondary sources. GraphPad Prism (version 7.4) facilitated data analysis, employing multiple linear regression and the Chi-square test for quantitative data analysis.


Results: The study in Muzaffarabad district revealed significant findings on COVID-19 vaccination. A noteworthy 83% participants displayed positive knowledge, alongside a 77.3% positive attitude. Vaccination status disparities emerged, with EPI reporting 29.6% fully vaccinated and 48.1% half vaccinated, while primary sources showed higher figures at 72.2% fully vaccinated and 8.6% half vaccinated, possibly reflecting differences in population size. CanSino proved most effective at 97.9%, with low post-vaccination COVID-19 cases (4.2%), mainly due to missed booster doses. Common side effects included pain at the injection site (55%), fever (47.5%), tiredness (29.2%), headache (23.3%), and muscle pain (21.1%).


Conclusion: In Muzaffarabad, people mostly have knowledge and express a positive attitude towards COVID-19 vaccines. Differences in vaccination numbers between primary and secondary data may be attributed to population sizes. Overall, the vaccination campaign represents a positive stride toward achieving a herd immunity and tackling global COVID-19 challenges in Muzaffarabad.

Abstract 204 | pdf Downloads 42

References

1. Yang L, Liu S, Liu J, Zhang Z, Wan, X, Huang B, Chen Y, Zhang Y. COVID-19: immunopathogenesis and Immunotherapeutics. Signal transduction and targeted therapy. 2020;5(1):128.
2. Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clinical Medicine. 2020;20(2):124-127.
3. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2023. https://covid19.who.int/
4. Wen Z, Zhang Y, Lin Z, Shi K, Jiu Y. Cytoskeleton-a crucial key in host cell for coronavirus infection. Journal of Molecular Cell Biology. 2020;12(12):968-979.
5. Mittal A, Manjunath K, Ranjan RK, Kaushik S, Kumar S, Verma V. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. PLOS PATHOGEN. 2020. https://doi.org/10.1371/journal.ppat.1008762
6. Chilamakuri R, Agarwal S. COVID-19: Characteristics and Therapeutics. Cells. 2020;10:206.
7. Hamre D, Procknow JJ. A New Virus Isolated from the Human Respiratory Tract. Experimental Biology and Medicine. 1966;121(1):190-193.
8. McIntosh K, Dees JH, Becker WB, Kapikian AZ, Chanock RM. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proceedings of the National Academy of Sciences of the United States of America. 1667;57(4): 933-940.
9. Forni G, Mantovani A. COVID-19 vaccines: where we stand and challenges ahead. Cell Death & Differentiation. 2021;28(2):626-639.
10. Cevik M, Grubaugh ND, Iwasaki A, Openshaw P. COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants. Cell. 2021;184(20):5077-5081.
11. Privor-Dumm L, Excler JL, Gilbert S, Karim SSA, Hotez, PJ, Thompson D, Kim JH. Vaccine access, equity and justice: COVID-19 vaccines and vaccination. BMJ Global Health. 2023;8(6):e011881.
12. World Health Organization. Status of COVID-19 Vaccines within WHO EUL/PQ Evaluation Process 2021. 2021. https://extranet.who.int/pqweb/key-resources/documents/status-covid-19-vaccines-within-who-eulpq-evaluation-process
13. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 vaccines. Jama. 2021;325(13):1318-1320.
14. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. International Journal of Infectious Diseases. 2022;114:252-260.
15. Palacios R, Patiño EG, Piorelli RDO, Conde MTRP, Batista AP, Zeng G, Xin Q, Kallas EG, Flores J, Ockenhouse CF, Gast C. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac–PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):1-3.
16. Nogrady B. Mounting evidence suggests Sputnik COVID vaccine is safe and effective. Nature. 2021;595(7867):339-340.
17. Mousa M, Albreiki M, Alshehhi F, AlShamsi S, Al Marzouqi N, Alawadi T, Alrand H, Alsafar, H, Fikri A. Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAE. Journal of Travel Medicine. 2022. https://doi.org/10.1093/jtm/taac036
18. World Health Organization. Evidence Assessment: Sinopharm/BBIBP COVID-19 Vaccine. 2021. https://cdn.who.int/media/docs/defaultsource/immunization/sage/2021/april/2_sage29apr2021_critical-evidence_sinopharm.pdf
19. AlHosani FI, Stanciole AE, Aden B, Timoshkin A, Najim O, Zaher WA, AlDhaheri FA, Al Mazrouie S, Rizvi TA, Mustafa F. Impact of the Sinopharm’s BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE). Vaccine. 2022;40(13):2003-2010.
20. Paixao ES, Wong KL, Alves FJO, de Araújo Oliveira V, Cerqueira-Silva T, Júnior JB, Machado TM, Junior EPP, Boaventura VS, Penna GO, Werneck GL, Rodrigues LC, Pearce N, Barreto ML, Barral-Netto M. CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study. BMC medicine. 2022;20(1):1-8.
21. Nisar MI, Ansari N, Malik AA, Ramzan Ali Lalani K, Chandna MA, Younus AM, Hasan Z, Khan U, Khalid F, Mahesar M, Omer SB. Assessing the Effectiveness of COVID-19 Vaccines in Pakistan: A Test-Negative Case-Control Study. Preprints with The Lancet. 2022. http://dx.doi.org/10.2139/ssrn.4112153
22. Hayat M, Uzair M, Ali Syed R, Arshad M, Bashir S. Status of COVID-19 vaccination around South Asia. Human Vaccines & Immunotherapeutics. 2022;18(1):2016010.
23. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2023. https://data.who.int/dashboards/covid19/cases?n=c
24. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, Giattino C, Rodés-Guirao L. A global database of COVID-19 vaccinations. Nature human behaviour. 2021;5(7):947-953.
25. Miao Y, Zhang W, Li Y, Wu J, Xu D, Gu J, Wang M, Wei W, Ye B, Miao C, Tarimo CS, Dong, W. Association between lifestyle and COVID-19 vaccination: a national cross-sectional study. Frontiers in Public Health. 2022;10:918743.
26. Singh PK, Anvikar A, Sinha A. COVID-19 related knowledge, attitudes, and practices in Indian Population: An online national cross-sectional survey. PloS one. 2022;17(3):e0264752.
27. Ahmed N, Hassan W, Rasool R, Fahim U, Shakil A, Khan KS. Knowledge, attitude and practices regarding COVID-19 among a cross-sectional sample from Karachi, Pakistan: descriptive data. Journal of Infectious Diseases and Epidemiology. 2020;6(5):164.
28. Abebe H, Shitu S, Mose A. Understanding of COVID-19 vaccine knowledge, attitude, acceptance, and determinates of COVID-19 vaccine acceptance among adult population in Ethiopia. Infection and drug resistance. 2021;14: 2015.
29. Kupek E. Low COVID-19 vaccination coverage and high COVID-19 mortality rates in Brazilian elderly. Revista Brasileira de Epidemiologia. 2021.
30. Richardson VL, Franco MAC, Márquez AB, Valdez LM, Ceronio LEC, Cruz VC, Gharpure R, Lafond KE, Yau TS, Azziz-Baumgartner E, Ávila MH. Vaccine effectiveness of CanSino (Adv5-nCoV) COVID-19 vaccine among childcare workers–Mexico, March–December 2021. Cold Spring Harbor Laboratory BMJ Yale. 2022.
31. Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, Moore Z, Zeng D. Effectiveness of Covid-19 vaccines over a 9-month period in North Carolina. New England Journal of Medicine. 2022;386(10):933-941.
32. Acuti Martellucci C, Flacco ME, Soldato G, Di Martino G, Carota R, Caponetti A, Manzoli L. Effectiveness of COVID-19 Vaccines in the General Population of an Italian Region before and during the Omicron Wave. Vaccines. 2022;10(5):662.
33. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, Pizarro A, Acevedo J, Leo K, Leon F, Sans C, Leighton P, Suárez P, García-Escorza H, Araos R. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. New England Journal of Medicine. 2021;385(10):875-884.
34. Alhazmi A, Alamer E, Daws D, Hakami M, Darraj M, Abdelwahab S, Maghfuri A, Algaissi A. Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia. Vaccines. 2021;9(6):674.
35. Abbas S, Abbas B, Amir S,Wajahat M. Evaluation of adverse effects with COVID-19 vaccination in Pakistan. Pakistan Journal of Medical Sciences. 2021;37(7):1959.
36. Tahir MJ, Saqlain M, Tariq W, Waheed S, Tan SH, Nasir SI, Ullah I, Ahmed A. Population preferences and attitudes towards COVID-19 vaccination: a cross-sectional study from Pakistan. BMC public health. 2021;21(1):1-12.
37. Neumann-Böhme S, Varghese NE, Sabat I, Barros PP, Brouwer W, van Exel J, Schreyögg J, Stargardt T. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. The European Journal of Health Economics. 2020;21(7):977-982.
38. Bacong AM, Haro-Ramos AY. Willingness to receive the COVID-19 vaccine in California: disparities by race and citizenship status. Journal of Racial and Ethnic Health Disparities. 2023;10(6):2911-2920.

Most read articles by the same author(s)